Gilead Sciences Inc
GILD
Company Profile
Business description
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Contact
333 Lakeside Drive
Foster CityCA94404
USAT: +1 650 574-3000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
17,600
Stocks News & Analysis
personal-finance
US stock market outlook: tariffs are 2025's wild card
Macrodynamic tailwinds persist, but stocks are already priced to perfection. Will tariffs derail the market in 2025?
stocks
10 cheap US dividend-growth stocks to buy
The stocks of these companies with a history of dividend increases look undervalued today.
stocks
The 10 best US dividend shares
These undervalued stocks with reliable dividends are worth considering.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,611.70 | 38.30 | 0.45% |
CAC 40 | 7,910.41 | 32.01 | -0.40% |
DAX 40 | 24,060.41 | 24.30 | 0.10% |
Dow JONES (US) | 42,259.99 | 417.25 | -0.98% |
FTSE 100 | 8,783.36 | 2.24 | 0.03% |
HKSE | 23,827.78 | 146.30 | 0.62% |
NASDAQ | 19,112.54 | 30.18 | -0.16% |
Nikkei 225 | 37,298.98 | 230.51 | -0.61% |
NZX 50 Index | 12,703.10 | 58.87 | 0.47% |
S&P 500 | 5,909.01 | 31.45 | -0.53% |
S&P/ASX 200 | 8,386.80 | 43.50 | 0.52% |
SSE Composite Index | 3,387.57 | 7.10 | 0.21% |